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www.sciencedirect.comEDITORIALAdverse eﬀects of exercise on respiratory system healthRegular exercise is recommended for the prevention & treat-
ment of a variety of diseases, but the effect of physical activity
on lung health has received less attention. In fact, given the
wrong combination of individual characteristics, environmen-
tal factors, & the nature of the activity, sports activities can
pose a threat to respiratory health. Clinicians should be famil-
iar with the risks associated with various activities to ensure
prompt diagnosis and appropriate management of exercise-in-
duced pulmonary disorders.
Risks of exercise
Exercise-induced asthma
Exercise-induced asthma (EIA) is a condition in which vigor-
ous physical activity triggers acute airway narrowing in per-
sons with increased airway activity. It is common, affecting
50–90% of all asthmatics. One theory ‘‘airway re-warming the-
ory’’ is based on airway cooling and assumes that the air move-
ment in the bronchial tree results in a decreased temperature of
the bronchi, which may also trigger a hyperemic response in an
effort to heat the airway. The result is a spasm in the bronchi.
The other one is the ‘‘hyperosmolarity theory’’, which suggests
that air movement through the airway results in relative drying
of the airway and leads to hypertonicity of the surface cells of
the airways. This, in turn, is believed to trigger pro-inﬂamma-
tory mediators cascade of events that results in bronchospasm.
Risk factors for development of EIA include: (1) Environmen-
tal factors e.g., chlorination in pools, insecticides and pesticides
used to maintain playing ﬁelds, fertilizers and herbicides used
to maintain playing ﬁelds, paints and other decorative sub-
stances for the playing ﬁelds, decreased temperature and
humidity of the inspired air and high pollen counts. (2) Asth-
mogenic agents e.g., b-blockers, Aspirin, Non-steroidal anti-
inﬂammatory drugs (NSAIDs), and Zanamivir. (3) Medical
conditions e.g., patient’s baseline airway reactivity, poorly con-
trolled asthma and allergic rhinitis, viral, bacterial, and otherPeer review under responsibility of The Egyptian Society of Chest
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cise-related factors e.g., high-intensity aerobic exercise appears
to be much more problematic than anaerobic exercise
P10 min provokes EIA. First-line treatment of EIA entails in-
haled short-acting b2-agonists and/or cromolyn sodium prior
to exercise, but a number of other asthma medications can also
be used if adequate control is not achieved.
Vocal cord dysfunction
Vocal cord dysfunction (VCD), also recognized as paradoxical
vocal cord motion (PVCM), is a condition where the larynx
exhibits paradoxical vocal cord adduction during and/or expi-
ration that occurs suddenly within few minutes of increased le-
vel of physical activity resulting in wheezing, dyspnea, cough,
& shortness of breath that mimics asthma. It is precipitated by
a trigger e.g., airway irritants (including gastric reﬂux, postna-
sal drip associated with sinusitis, and airborne particle/pollu-
tants), emotional stress, extreme temperatures, or endurance
exercise. Criteria for diagnosis of VCD include: (1) Presence
of symptoms including wheeze, cough, dyspnea, stridor,
hoarseness. (2) Laryngoscopic conﬁrmed adduction of vocal
cords inspiration and/or expiration. (3) Absence of gagging
or coughing during laryngoscopy. (4) Presence of a posterior
glottic chink. (5) Exclusion of alternative vocal cord disease.
Aside from treating causes of laryngeal irritation, speech ther-
apy, sometimes accompanied by psychological counseling, is
the mainstay of long-term management.
Vocal cords during inspiration in both normal patient (A)
& patient with VCD (B). Note the characteristic posterior
chinking in the vocal cords of patient B.is. Production and hosting by Elsevier B.V.
9.005
234Flow-volume loop in a normal patient (A) and in a patient
with extrathoracic airway obstruction (B). Note the blunting
of the inspiratory portion in the patient with extrathoracic air-
way obstruction.
Exercise at barometric extremes
Diving can be undertaken in three fundamentally differentman-
ners: (1) Breath-hold diving, (2) ‘‘Bounce’’ diving with breathing
apparatus and (3) Saturation diving. For every 10 ms descent
in water, ambient pressure increases by 100 kPa, equivalent to
1 atmosphere (1 bar). The volume of a givenmass of gas changes
inversely in proportion to pressure to Boyle’s law. The gas in
bodily cavities such as the lungs is therefore subject to compres-
sion during descent & expansion during ascent. Thismay lead to
tissue damage. Partial pressure of gases increases in direct pro-
portion to the increase in ambient pressure. Greater quantities
of inert gas, mainly nitrogen, therefore dissolve in tissues at
depth and come out on ascent. The density of inhaled gas in-
creaseswith pressure, restricting breathing. Immersion displaces
blood from the periphery into the thorax, reducing lung volume.
Work of breathing increases due to a combination of increased
gas density, increased hydrostatic pressure, and altered respira-
tory mechanics, breathing apparatus adds dead space. During
diving, carbon dioxide retention may result from the above
listed effects on the body.Diving-induced Pulmonary Barotrauma includes: pneumo-
thorax ± tension, pneumomediastinum, surgical emphysema,arterial gas embolism, and decompression sickness. Subjects
with certain lung diseases such as emphysema & cystic ﬁbrosis
are at increased risk of pulmonary barotrauma. Treatment of
arterial gas embolism and severe decompression sickness in-
volves use of 100% supplemental oxygen and hyperbaric oxy-
gen therapy when available.
At the other end of the barometric spectrum, exercise at ele-
vations greater than 2500 m places individuals at risk of acute
mountain sickness (AMS), high-altitude cerebral edema
(HACE), and high-altitude pulmonary edema (HAPE). The
cardinal feature of AMS is headache, which is typically accom-
panied by variable degrees of malaise, anorexia, nausea, vom-
iting, and poor sleep. AMS is a common, self-limited illness,
assuming there are no further rapid gains in elevation. HACE
is believed to be a more severe manifestation of AMS and is
associated with neurologic deﬁcits caused, at least in part, by
cerebral edema. In contrast to AMS, HACE is life threatening
and can manifest with ataxia, upper motor neuron signs,
intractable vomiting, stupor, and coma. Allowing time for
acclimatization is the best approach to preventing these ill-
nesses. However, pharmacologic prevention and treatment of
AMS with acetazolamide or dexamethasone is often indicated.
Dexamethasone is the drug of choice to prevent HACE and is
coupled with descent to manage individuals with HACE.
HAPE is a cause of potentially lethal non-cardiogenic pulmon-
ary edema and is typically seen at elevations greater than 3000
m. The risk increases with increasing elevation, faster rate of
ascent, and vigorous exertion. Individuals with a previous his-
tory of HAPE are at increased risk of recurrence. HAPE ap-
pears to be caused by severe, non-uniform pulmonary
arterial vasoconstriction in a vulnerable subset of persons with
an inadequate ventilatory response to hypoxia. This in turn re-
sults in excessive perfusion of, and injury to, portions of the
pulmonary capillary bed, with subsequent hypoxemia from
leakage of cells, proteins, and ﬂuid into the interstitium and
alveolar spaces. As with AMS and HACE, allowing sufﬁcient
time for acclimatization, with gradual, step-wise exposure to
increasing altitude, is the mainstay of prevention. Pharmaco-
logic prophylaxis, including phosphodiesterase inhibitors and
the calcium channel blocker nifedipine, are appropriate for
individuals with a prior history of HAPE. The mainstay of
treating HAPE is supplemental oxygen, limiting physical activ-
ity, and/or descent to lower altitude. Nifedipine may offer
additional beneﬁt, particularly if the patient is unable to
descend.
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